By: Inder Paul Singh, MD, Moderator; Michael Chaglasian, OD, FAAO; Constance Okeke, MD, MSCE; and Tony Realini, MD, MPH
This course has expired. You can still review the content but course credit is no longer available.
ACTIVITY DESCRIPTION Topical pharmacologic therapy is the mainstay primary treatment for patients with primary open-angle glaucoma (POAG) and ocular hypertension. Unfortunately, many patients need to be on multiple medications and different classes of drugs before there is adequate intraocular pressure (IOP) control. And for some patients, visual field loss will progress despite adequate IOP control. Until recently, no new topical pharmacologic treatments had been approved in the United States for more than a decade. Two new formulations were approved in late 2017. Ophthalmologists and other health care providers may not be familiar with potential new treatments for glaucoma, the latest clinical studies evaluating treatment nor the mechanism of action of topical medications.
This activity is supported by an unrestricted educational grant from Bausch + Lomb.
Upon completion of this activity, the participant should be able to:
ACCREDITATION STATEMENT
Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Evolve is an approved COPE Administrator.
CREDIT DESIGNATION STATEMENT
Evolve designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This course is COPE approved for 1.0 hours of CE Credit for Optometrists.
COPE Course ID: 62629-GL
COPE Event ID: 117502
Inder Paul Singh, MD, Moderator
The Eye Centers of Racine & Kenosha
Racine, Wisconsin
Michael Chaglasian, OD, FAAO
Associate Professor, Illinois College of Optometry
Chief of Staff, Illinois Eye Institute
Chicago, Illinois
Constance Okeke, MD, MSCE
Assistant Professor of Ophthalmology
Eastern Virginia Medical School
Virginia Eye Consultants
Norfolk, Virginia
Tony Realini, MD, MPH
Professor
Director Glaucoma Fellowship
Director, Clinical Research, West Virginia University
Morgantown, West Virginia
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
Inder Paul Singh, MD, and/or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant and Speaker’s Bureau: Allergan plc., Alcon, Bausch + Lomb, Ellex, Glaukos, Ivantis, New World Medical, and Shire. Grant/Research Support: Ellex, Glaukos, and Sight Sciences.
Michael Chaglasian, OD, FAAO, and/or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan plc., Carl Zeiss Meditec and Reichert. Grant/ Research Support: Heidelberg and TopCon Medical. Speaker’s Bureau: Aerie Pharmaceuticals, Bausch + Lomb, Glaukos, and Novartis.
Constance Okeke, MD, MSCE, and/or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie Pharmaceuticals, Alcon, Allergan, Bausch + Lomb, Ellex, Glaukos, Medscape, Novartis, Santen and Sight Sciences. Grant/ Research Support: Glaukos. Speaker’s Bureau: Aerie Pharmaceuticals, Alcon, Bausch + Lomb, Ellex, Glaukos, Medscape, and NeoMedix.
Tony Realini, MD, MPH, and/or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie Pharmaceuticals, Ellex, iStarMed, New World Medical, Palvella, and ViSci.
Editorial Support Disclosures
Erin K. Fletcher, MIT, director of compliance and education; Susan Gallagher-Pecha, director of client services and project management; Cassandra Richards, director of education development, Evolve; and Michelle Dalton, writer, have no financial relationships with commercial interests. Jaya Kumar, MD, peer reviewer, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, Glaucoma Today, Modern Optometry, or Bausch + Lomb.
